Patents by Inventor Keith L. March

Keith L. March has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190153087
    Abstract: EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro-apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections.
    Type: Application
    Filed: February 23, 2017
    Publication date: May 23, 2019
    Inventors: Natalia Bogatcheva, Matthias Alexander Clauss, Keith L. March
  • Publication number: 20180243158
    Abstract: A manual soft tissue device including a pressure applicator and a sensor member configured to determine at least one of a magnitude, an angle, a stroke frequency, and a rate of force applied to soft tissue by the pressure applicator.
    Type: Application
    Filed: September 16, 2016
    Publication date: August 30, 2018
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Mary T. Loghmani, Sohel Anwar, Ahmed Alotaibi, Keith L. March, Stanley Chien
  • Publication number: 20180220642
    Abstract: The present disclosure provides methods and compositions for treating tissue to preserve and/or rescue tissue from ischemic and/or reperfusion injury and methods for assessing ischemic and/or injuries in cardiac tissue. The disclosed compositions comprise at least a portion of mesenchymal stem cell-conditioned medium.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Keith L. March, Meijing Wang
  • Publication number: 20150147409
    Abstract: A combination of therapeutic factors derived from non-adherent or poorly adherent stromal vascular fraction (SVF) cells exposed to protein-free basal medium are disclosed.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventors: Keith L. March, Brian H. Johnstone
  • Publication number: 20130006339
    Abstract: Implantable biomedical device leads comprising liquid conductors. In an exemplary embodiment of a lead for use in a biomedical application of the present disclosure, the lead comprises a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition comprising a metal in a liquid state at or below about 98° F. In another embodiment, the electrically conductive composition is selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof. In various embodiments, the metallic electrically conductive composition is used along with a second non-metallic electrically conductive composition such as a conductive polymer, an electrically conductive liquid, an electrically conductive gel, or combinations thereof.
    Type: Application
    Filed: December 13, 2010
    Publication date: January 3, 2013
    Inventors: Keith L. March, William J. Combs, Aaron Matthew Kyle, Nichole Marilyn Leahy-Glass
  • Publication number: 20120269775
    Abstract: Methods are provided for promoting angiogenesis in a mammal, such methods including the administration of therapeutic quantity of adipose-derived stromal cells to a mammal such that therapeutic angiogenesis occurs.
    Type: Application
    Filed: October 21, 2011
    Publication date: October 25, 2012
    Inventors: Keith L. March, Jalees Rehman
  • Publication number: 20120129253
    Abstract: Adipose tissue-derived stromal cells and methods of isolating and using the same. In at least one embodiment of isolated adipose tissue-derived stromal cells of the present disclosure, the cells are isolated by performing adipose tissue resection or suction on a mammalian patient, dissecting tissue obtained from said tissue resection or suction and dissociating said tissue into a cell suspension, removing adipocytes from the cell suspension, culturing the adipocyte-depleted cell suspension in EGM-2-MV media, and isolating adipose tissue-derived stromal cells secreting vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and granulocyte-colony stimulating factor (G-CSF).
    Type: Application
    Filed: February 1, 2012
    Publication date: May 24, 2012
    Inventors: Keith L. March, Jalees Rehman
  • Patent number: 8067234
    Abstract: Methods are provided for isolating adipose derived stromal cells from an animal by extracting adipose tissue from the patient, dissecting the tissue, dissociating the tissue into a cell suspension, removing the adipocytes, exposing the cell suspension to red cell lysis buffer, and isolating adipose derived stromal cells.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: November 29, 2011
    Assignee: Tissue Genesis, Inc.
    Inventors: Keith L. March, Jalees Rehman
  • Publication number: 20110208162
    Abstract: The present invention relates to a methods, compositions, and admixtures which prevent the aggregation of a population of adipose stromal cells (ASCs), such as an isolated population of adipose stromal cells. In some embodiments, the present invention relates to admixtures and methods of use thereof comprising a population of ASC and a modulator of ASC aggregation. In some embodiments, a modulator of ASC aggregation includes, for example, ionic agents (e.g., heparin), chelating agents (e.g., EDTA), proteolytic agents.(e.g., trypsin or dispase), and agents which inhibit the expression of cell surface receptors and molecules on the surface of ASCs (e.g., inhibitors of integrins expression). In some embodiments, the methods to block ASC aggregation and the admixtures are useful in use of the ASCs to treat various diseases and/or conditions, and increases the safety and/or efficiency of ASCs.
    Type: Application
    Filed: October 26, 2009
    Publication date: August 25, 2011
    Applicant: Indiana University Rsearch and Technology Corporation
    Inventors: Keith L. March, Brian H. Johnstone
  • Publication number: 20100143476
    Abstract: Cell based compositions and methods are provided for inducing the formation of vascular structures in a warm blooded vertebrate. In one embodiment the composition comprises purified endothelial progenitor cells and adipose stromal cells and the method of stimulating the formation of vascular structures comprises the steps of implanting the composition in a host organism.
    Type: Application
    Filed: February 14, 2008
    Publication date: June 10, 2010
    Inventors: Keith L. March, Brian Johnstone, Dmity O. Traktuev
  • Publication number: 20100022005
    Abstract: Methods are provided for isolating adipose derived stromal cells from an animal by extracting adipose tissue from the patient, dissecting the tissue, dissociating the tissue into a cell suspension, removing the adipocytes, exposing the cell suspension to red cell lysis buffer, and isolating adipose derived stromal cells.
    Type: Application
    Filed: September 29, 2009
    Publication date: January 28, 2010
    Inventors: Keith L. March, Jalees Rehman
  • Patent number: 6524298
    Abstract: A system for treating a patient's heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a means to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission means having a laser radiation emitting means and an delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.
    Type: Grant
    Filed: February 27, 2001
    Date of Patent: February 25, 2003
    Assignee: CardioGenesis Corporation
    Inventors: Keith L. March, Michael Aita, Randy Kesten, Craig Smith
  • Publication number: 20020052634
    Abstract: A system and method for increasing the efficacy of stimulation signal therapy applied to selected tissue at a treatment site is disclosed. The method includes determining a stimulation signal capable of effecting desired results on the selected tissue and selectively modulating the stimulation signal such that the desired effect is achieved at the treatment site. The system includes a signal generator capable of generating a stimulation signal configured to produce a desired biologic effect on selected tissue at the treatment site, a modulator configured to selectively modulate the stimulation signal such that the stimulation signal correlates with at least one characteristic of the selected tissue and an emitter configured to apply the stimulation signal to the selected tissue.
    Type: Application
    Filed: November 1, 2001
    Publication date: May 2, 2002
    Inventor: Keith L. March
  • Patent number: 6371905
    Abstract: A system and method for treating cardiovascular disease utilizes electromagnetic fields (EMF) applied by non-invasive or minimally invasive procedures. The EMF is applied to existing vascular structure to modulate blood flow and blood vessel growth in the patient. In one embodiment, a structure of electromagnetic coils is placed about a desired treatment zone to apply an EMF to the zone on the order of 104-10 T. For cardiac angiogenesis, coils can be positioned on the anterior chest wall and on the back at the level of the heart. Various coil configurations are contemplated to yield appropriate field intensities at the treatment zone. In another embodiment, coils can be implanted within the patient and placed within or overlying the treatment zone incorporating several aspects, such as frequency components, the use of ca carrier frequency, pulse shape, duty cycle, and total time exposure to the EMF.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: April 16, 2002
    Inventor: Keith L. March
  • Patent number: 6333347
    Abstract: Methods and compositions are provided for intra-pericardial administration of anti-microtubule agents, suitable for use in treating or preventing a variety of diseases of the pericardium, heart, or, coronary vasculature.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: December 25, 2001
    Assignee: Angiotech Pharmaceuticals & Advanced Research Tech
    Inventors: William L. Hunter, Keith L. March
  • Patent number: 6267717
    Abstract: An apparatus for treating a body structure with radiation and a method for using the same. The apparatus comprising a concentrator for receiving a solution comprising a radioactive material and for increasing the concentration of the radioactive material in solution; a calibrator operatively associated with the concentrator for measuring a level of radiation associated with the radioactive material; and a delivery unit for transferring the solution directly from the apparatus to a balloon catheter.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: July 31, 2001
    Assignee: Advanced Research & Technology Institute
    Inventors: Hans-Peter Stoll, Keith L. March, Gary Hutchins
  • Patent number: 6224584
    Abstract: A system for treating a patient's heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a means to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission means having a laser radiation emitting means and an delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: May 1, 2001
    Assignee: Eclipse Surgical Technologies, Inc.
    Inventors: Keith L. March, Michael Aita, Randy Kesten, Craig Smith
  • Patent number: 6200259
    Abstract: A system and method for treating cardiovascular disease utilizes electromagnetic fields (EMF) applied by non-invasive or minimally invasive procedures. The EMF is applied to existing vascular structure to modulate blood flow and blood vessel growth in the patient. In one embodiment, a structure of electromagnetic coils is placed about a desired treatment zone to apply an EMF to the zone on the order of 104−10 T. For cardiac angiogenesis, coils can be positioned on the anterior chest wall and on the back at the level of the heart. Various coil configurations are contemplated to yield appropriate field intensities at the treatment zone. In another embodiment, coils can be implanted within the patient and placed within or overlying the treatment zone. An EMF dosage plan can be developed for the patient and specific treatment zone incorporating several aspects, such as frequency components, the use of a carrier frequency, pulse shape, duty cycle, and total time exposure to the EMF.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: March 13, 2001
    Inventor: Keith L. March
  • Patent number: 5997525
    Abstract: A system for treating a patient's heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a means to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission means having a laser radiation emitting means and an delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: December 7, 1999
    Assignee: Cardiogenesis Corporation
    Inventors: Keith L. March, Michael Aita, Randy Kesten, Craig Smith
  • Patent number: 5840059
    Abstract: A system for treating a patient's heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a way to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission catheter that emits laser radiation and has delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignees: CardioGenesis Corporation, Indiana University Foundation, Columbia University
    Inventors: Keith L. March, Michael Aita, Randy Kesten, Craig Smith